Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Indaptus Therapeutics, Inc. (INDP)

0.4511
-0.0189
(-4.02%)
As of 2:29:46 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for INDP

Recent News: INDP

View More
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
GlobeNewswire last month
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
GlobeNewswire last month
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewswire last month
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
GlobeNewswire last month
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025
GlobeNewswire last month
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
GlobeNewswire last month
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
GlobeNewswire 2 months ago
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
GlobeNewswire 2 months ago
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire 3 months ago
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
GlobeNewswire 3 months ago
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire 5 months ago
View More

Related Tickers

GLYC GlycoMimetics, Inc.
0.2692
+2.48%
 
PMN ProMIS Neurosciences, Inc.
0.6534
+0.52%
 
ACET Adicet Bio, Inc.
0.6949
+10.56%
 
OVID Ovid Therapeutics Inc.
0.3201
+1.55%
 
QLGN Qualigen Therapeutics, Inc.
3.5600
-0.28%
 
NNVC NanoViricides, Inc.
1.2800
-3.76%
 
IPHA Innate Pharma S.A.
2.2650
+1.12%
 
RNXT RenovoRx, Inc.
1.0100
+2.01%
 
VRPX Virpax Pharmaceuticals, Inc.
0.2750
+5.77%
 
PALI Palisade Bio, Inc.
0.8046
-0.67%
 
Waiting for permission
Allow microphone access to enable voice search

Try again.